Marco Cattaneo, M.D.

Professor of Internal Medicine at Università degli Studi di Milano. He has been Post-Doctoral Fellow at McMaster University, Hamilton (Ontario), Guest and Visiting Scientist at McMaster University, Temple University, Philadelphia (PA), The Scripps Research Institute, La Jolla (CA). In 2001 he was awarded the International Society on Thrombosis and Haemostasis (ISTH) 10th Biennial Award for Contributions to Haemostasis and Thrombosis. Editor/Associate Editor/member of Editorial Board/Advisory Board for high-tier journals, including Journal of Thrombosis and Haemostasis, Thrombosis Research, Haematologica, Platelets, Thrombosis and Haemostasis, Arteriosclerosis, Thrombosis and Vascular Biology. Chair of the Working Party on Platelet Aggregation, Chair of the Scientific Subcommittee on Platelet Physiology, Scientific and Standardization Committee (ISTH). Member of the ISTH Council 2010-2016. President-Elect, President and Past-President of SISET, the Italian Society on thrombosis and hemostasis, 2002-2008. Member of the Thrombosis Working Group Nucleus of the European Society of Cardiology, 2010-2016. Chairman of the Eurthombosis Summit, 2015. Co-Chiarman of the  XXXVII Congress of ISTH, 2020. Main research interests: pathophysiology of primary hemostasis, pharmacology of antiplatelet agents, risk factors for thromboembolism. Author of 420 original publications, with an H-index of 76 (Scopus).

Gili Kennet

Director of the Israel National Hemophilia Center and Thrombosis Institute, Sheba Medical Center and head of Amalia Biron Research Institute of Thrombosis and Hemostasis, Tel Aviv University. She also serves as director of the international PedNet Research Foundation.

Gili Kenet is a Pediatric Hematologist, Professor and former Chair of the Hematology Department at Tel Aviv University. Her research projects have been focused on neonatal hemostasis, research of new therapy modes applied for people with hemophilia and severe bleeding disorders. Prof. Kenet pioneered in gene therapy clinical trials and novel non replacement Hemophilia therapies. She was awarded grants for pediatric hematology research, study of rFVIIa mode of action, epidemiology of inhibitor evolution, personalized tailoring of hemophilia therapy by application of global hemostasis assays and recently - gene therapy murine models.

Professor Kenet is the author of over 320 peer reviewed scientific publications, review articles and book chapters, editorial board member of the Haemophilia journal. She is an active member of the WFH, American Society of Hematology, former Chairperson of the Pediatric and Peri-natal Hemostasis Scientific Subcommittee (SSC) of ISTH & co-chair of FVIII/FIX and rare bleeding disorders, member of educational committees of EHA and EMLTD.

She also published one poetry book.

Georgia Kaiafa

Name:  Georgia KAIAFA

Date of birth:  30.05.62

Education: Αristotle University of Thessaloniki, Medical School 1980-1996

 

Professional qualifications:

MBBS	1987
Doctorate thesis	2005
Board Certification in Haematology	1996
Visiting Research Associate in Dept of Haematological Medicine, King’s College Hospital, London, UK	2012 (6 months)
Excellence of Thrombosis	2020

 

CURRENT APPOINTMENTS:

Coordinator in Northern Greece Office of Health Sector	2005 to date
Lecturer of Haematology	2007 to 2015
Assistant Professor of Haematology	2015 to 2021
Associate Professor of Haematology and Tromboembolic Diseases	2021 to date
AHEPA University Hospital
Hematology Department, 1st Propeudetic Internal Medicine Clinic
1, Stilponos Kyriakidi Street
Thessaloniki, 54636

 

NATIONAL & INTERNATIONAL RECOGNITION/COMMITTEES:

• Hellenic Society of Haematology
• Society of Medicine of Thessaloniki
• Greek Society of Study and Treatment of AIDS
• Greek Society of Infection Diseases
• Greek Society of Immunology
• Society of Pathologists-Oncologists of Greece
• Diabetic Society of Northern Greece
• Hellenic Stroke Organization
• European Stroke Organization
• Excellence in Thrombosis (Hellenic Study Institute of Thrombosis and Antithrombotic Therapy)
• Herakleitos II, Evaluator of Research protocol of
• CME and Life Long Learning Program of Ministry of Education
• EMLTD

 

Reviewer

1. Journal of Pancreas
2. Case Reports in Hematology
3. Thrombosis Research
4. Current Vascular Pharmacology
5. Indian Heart Journal
6. Anemia
7. International Journal of Hematology Research (μέλος Editorial Board)
8. HIPPOKRATIA JOURNAL
9. To 3 Greeks Journals

 

Participation to programs  of Postgraduate Students   (Grreks & International)	15
Research trials & protocols
PI	26
SI	5
Publications
Chapter of books	23
Abstracts of Greek conferences proceedings or book of abstracts	138
Abstracts in International conferences published in International Journals	94
Full articles in Greek Journals	25
Speaker in Congress	118
Chairman in Congress	22
Supervisor / Committee of PhDs	5/12
Full papers published in International Journals included PubMed, Scopus	95

Prof. Vittorio Pengo M.D. (CV as of November 19, 2022)

Mailing Address: Thrombosis Research Laboratory, via Orus 2/B, 35129 Padova, Italy
Tel. +39 49 8212377  e-mail: vittorio.pengo@unipd.it

 

M.D. degree	University of Padova 1974
Residency	Internal Medicine, University of Padova
Certification	Internal Medicine 1980 Cardiology 1985
Post Graduate training	Clinical Medicine 1974-1983 Research Fellow, Cardeza Foundation, Philadelphia, PA, USA 1984-1985 Visiting scientist, Cardeza Foundation, Philadelphia, PA, USA, 1988 Clinical Cardiology 1988-
Clinical Interests	Primary/secondary prevention and treatment of venous and arterial thromboembolism
Research Interests	Pathophysiology and treatment of thrombosis.
Professional activity	Professor of Cardiovascular Medicine, Department of Cardiac Thoracic and Vascular Sciences, and Director of Thrombosis Center, University of Padova School of Medicine, Padova Italy (1988-2019)
Senior Scientist	University of Padova and Arianna Foundation on Anticoagulation (2019-) Reference Lab of APS action America (2014-)
Study awards - scholarships - grants	-Study Award on "Coagulation and Liver Diseases" arranged by the University of Padua. AA 1981-1982. - Two-year scholarship (1984-1985) for studies on: "Calciparin and secondary prevention of heart attack" arranged by Italfarmaco SpA and accepted by the Institute of Clinical Medicine University of Padua. -Contribution from the Vittorio Tonolli Cultural Foundation for Cardiology for travel expenses to the USA for studies in the field of thrombosis. - Award of excellence in scientific research in the years 1996-2000 conferred by the University Scientific Commission (area 7). Department Booklet 'Scientific Activity 2000 page 69.
Scientific societies - associations - commissions	-Founder of the Italian Association of Anticoagulated Patients (AIPA) (1987) -Chairman of the National Scientific Committee of the Federation of Associations of Patients on Treatment with Oral Anticoagulants (FEDER-AIPA) from 1995 to 2000. - Member of the steering committee of the Italian Society of Homostasis and Thrombosis (Siset) 1996 - Member of the editorial board of the journal 'Dialogue on drugs' (1999-2009). -Component of the European Forum for the study of antiphospholipid antibody syndrome -President of the Federation of Anticoagulated Surveillance Centers (FCSA) yrs 2000-2003 - Member of the working group of the Ministry of Health for the issuance of guidelines on therapy with oral anticoagulants. -Chairman of the Scientific Standardization Committee (SSC) on antiphospholipid antibodies 2007-2009 -President of the European and Mediterranean League against Thrombotic Diseases (EMLTD) 2016-2018

 

Reviwer for the following Journals:

New England Journal of Medicine, Circulation, Lancet, Blood, Journal of Thrombosis and Haemostasis, Thrombosis and Haemostasis, Thrombosis Research, American Journal of Cardiology, Haematologica, American Journal of Hematology, Journal of Cardiovascular Medicine, European Journal of Clinical Investigation, European Journal of Internal Medicine, Canadian Medical Association Journal

Associate Editor of Internal and Emergency Journal since 2011

Editorial Board member of Journal of Thrombosis and Haemostasis since 2003

 

Research activity

432 cited documents in International Journals (Scopus)

Total Citations: 20520, H-index: 68 (Scopus).

 

TWENTY MOST CITED PAPERS

 

1 Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism

 Pengo, V., Lensing, A.W.A., Prins, M.H., (...), Iliceto, S., Prandoni, P.     2004     

New England Journal of Medicine 350(22), pp. 2257-2264+2323

 

2

Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT)     Palareti, G., Leali, N., Coccheri, S., (...), Berrettini, M., Musolesi, S.       1996      Lancet

348(9025), pp. 423-428

 

3

Update of the guidelines for lupus anticoagulant detection

 Pengo, V., Tripodi, A., Reber, G., (...), Galli, M., De groot, P.G. 2009     

Journal of Thrombosis and Haemostasis 7(10), pp. 1737-1740

 

4

D-dimer testing to determine the duration of anticoagulation therapy Palareti, G., Cosmi, B., Legnani, C., (...), Lensing, A.W.A., Tripodi, A.              2006     

New England Journal of Medicine 355(17), pp. 1780-1789

 

5

The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients

 Prandoni, P., Noventa, F., Ghirarduzzi, A., (...), Simioni, P., Pagnan, A. 2007     

Haematologica 92(2), pp. 199-205+III-IV

 

6

The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants               Thiagarajan, P., Pengo, V., Shapiro, S.S.              1986     

Blood 68(4), pp. 869-874

 

7

Chronic thromboembolic pulmonary hypertension

 Kim, N.H., Delcroix, M., Jenkins, D.P., (...), Pengo, V., Mayer, E.             2013     

Journal of the American College of Cardiology 62(25 SUPPL.), pp. D92-D99

 

8

Clinical course of high-risk patients diagnosed with antiphospholipid syndrome

 Pengo, V., Ruffatti, A., Legnani, C., (...), Padayattil Jose, S., Iliceto, S.   2010     

Journal of Thrombosis and Haemostasis 8(2), pp. 237-242

 

9

Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies    Ruiz-Irastorza, G., Cuadrado, M.J., Ruiz-Arruza, I., (...), Tektonidou, M., Khamashta, M.          2011     

Lupus 20(2), pp. 206-218

 

10

PAIMS 2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2           Dalla-Volta, S., Palla, A., Santolicandro, A., (...), Marini, M.G., Visani, L.        1992     

Journal of the American College of Cardiology 20(3), pp. 520-526

 

11

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans          Takahashi, H., Wilkinson, G.R., Nutescu, E.A., (...), Kijima, S., Echizen, H.         2006     

Pharmacogenetics and Genomics 16(2), pp. 101-110

 

12

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance             Scordo, M.G., Pengo, V., Spina, E., (...), Gusella, M., Padrini, R.           2002     

Clinical Pharmacology and Therapeutics 72(6), pp. 702-710

 

13

Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: A multicenter prospective study

Pengo, V., Ruffatti, A., Legnani, C., (...), Jose, S.P., Iliceto, S.      2011     

Blood 118(17), pp. 4714-4718

 

14

Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome

 Pengo, V., Denas, G., Zoppellaro, G., (...), Gerosa, M., Banzato, A.         2018     

Blood 132(13), pp. 1365-1371

 

15

The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: An international multicenter study

 De Laat, B., Pengo, V., Pabinger, I., (...), Mertens, K., De Groot, P.G.     2009     

Journal of Thrombosis and Haemostasis 7(11), pp. 1767-1773

 

16

Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: A systematic review

Open Access

Iorio, A., Kearon, C., Filippucci, E., (...), Siragusa, S., Palareti, G.              2010     

Archives of Internal Medicine 170(19), pp. 1710-1716

 

17

A comparison of the safety and efficacy of oral antiocoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy           Palareti, G., Legnani, C., Lee, A., (...), Moia, M., Coccheri, S. 2000     

Thrombosis and Haemostasis 84(5), pp. 805-810

 

18

Antibody profiles for the diagnosis of antiphospholipid syndrome         Pengo, V., Biasiolo, A., Pegoraro, C., (...), Noventa, F., Iliceto, S.       2005     

Thrombosis and Haemostasis 93(6), pp. 1147-1152

 

19

The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism         Douketis, J.D., Gu, C.S., Schulman, S., (...), Pengo, V., Prandoni, P.      2007     

Annals of Internal Medicine 147(11), pp. 766-774

 

20

EULAR recommendations for the management of antiphospholipid syndrome in adults

 Tektonidou, M.G., Andreoli, L., Limper, M., (...), Tincani, A., Ward, M.M.          2019     

Annals of the Rheumatic Diseases 78(10), pp. 1296-1304

Lina Badimon

Prof. Lina Badimon is the Director of the Cardiovascular Science Program (ICCC) at the Hospital Santa Creu and San Pau, Director of the Cardiovascular Research Chair of the Autonomous University of Barcelona, Professor at the National Research Council of Spain (CSIC), and Director of the UNESCO Chair in Biomedical Sciences Training and Research. She is Visiting Professor of Manchester Metropolitan University. Her research activities focus on cardio-metabolic diseases, thrombosis, atherosclerosis and ischemic heart disease. She has published over 570 articles in highly qualified scientific journals with her work highly quoted in the scientific literature (H-index: 84. Number of citations: >62,000. ORCID number: 0000-0002-9162-2459). She has written more of 250 reviews and book chapters.

Hrvoje Budincevic

Hrvoje Budincevic, Croatia

Assist. prof. Hrvoje Budincevic, MD, PhD, FEAN, FESO, is a consultant neurologist with a subspecialisation in intensive care medicine and cerebrovascular diseases. He works at the Sveti Duh University Hospital in Zagreb (Croatia), where he is Deputy Head of the Department of Neurology and Head of Stroke and Intensive Care Unit.  He earned his Ph.D. degree in 2014 with the thesis: Impact of Anticoagulant Therapy on the Outcome in Ischemic Stroke Patients with Atrial Fibrillation. In 2018, he became an assistant professor of neurology at the University of Osijek. In 2017, he became a Fellow of the European Stroke Organisation (ESO); in 2020, he became a Fellow of the European Academy of Neurology (EAN). He is one of the course directors of the traditional Summer Stroke School in Dubrovnik (www.croatianstrokesociety.org).

Gregor Tratar

Gregor Tratar is a specialist of internal medicine and of cardiology with vascular medicine. He is currently the head of the outpatient VTE department at the University Medical Centre Ljubljana. He is also an assistant professor at the Department of Internal Medicine in the Faculty of Medicine at the University of Ljubljana. His research work is focused on fibrinolysis, anticoagulant treatment and management of patients with VTE.

Ileana Desormais

M.D., Ph.D, Vascular Medicine, Geriatric and Public Health

Senior Staff Physician, Department of Vascular Surgery and Angiology Dupuytren University Hospital Center of Limoges, France

Scientific Research Associate, main and co-investigator -  Inserm U1094, IRD U270, Limoges University, EpiMaCT - Epidemiology of chronic diseases in tropical zone, Institute of Epidemiology and Tropical Neurology, OmegaHealth, Limoges, France

ESC Peripheral Arterial Disease Working Group; ESC Task Force member for CVD Prevention, ESC/ESH Arterial Hypertension and Peripheral Arterial Disease Guidelines.

Research activities focused on cardio-vascular pathology, atherosclerosis, and thrombosis

Clinical interest in primary/secondary prevention and treatment of venous and arterial thromboembolism.

Luciana Ricca Gonçalves

Obtained her M.D. degree in Medicine in Oporto University, Portugal, in 1987.

She did her residency in Imuno-hemotherapy at the Department of Transfusion Medicine and Centre of Thrombosis and Hemostasis, at Centro Hospitalar Universitário São João (CHUSJ) in Oporto (1990-1995).

At present, she is a graduate specialist working at the Department of Transfusion Medicine and Centre of Thrombosis and Hemostasis, at CHUSJ. She is the coordinator of the Apheresis and Cryobiology Unit in CHUSJ since 1996.

Since her graduation, she has always been interested in the field of ​​thrombosis and hemostasis, in particular the pathophysiology of thrombosis and antithrombotic therapies, which is reflected in her daily work and scientific activity.

Since 2006, she is co-responsible for the Thrombophilia Unit at CHUSJ.

She is member of the Multidisciplinary Working Group for the Prevention of Thromboembolic Disease.

Co-founder and president of the Portuguese Association of Thrombosis and Hemostasis (APTH).

Author e co-author of scientific papers and book chapters.

Reviewer of several medical journals.

Member of the Scientific Committee of the journal” Acta Médica Portuguesa”.

Since October 2023, President of the Section of Immuno-hemotherapy of the Portuguese Medical Association.